You are here: Industry Insights > Acute Myeloid Leukemia

News List

FAQs About Rydapt (Midostaurin): Understanding Its Uses and Benefits PharmaSources
November 17, 2023
The recent approval of Rydapt (Midostaurin) by the FDA has generated a lot of interest and questions regarding this new targeted therapy for acute myeloid leukemia (AML) and aggressive systemic mastocytosis (ASM).
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China PharmaSources
September 19, 2024
InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.
FDA Approves Onureg (azacitidine tablets) as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia drugs.com
September 23, 2020
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Onureg (azacitidine 300 mg tablets.
Invivoscribe Launches New Division for Drug Development. Licenses Small Molecule Inhibitors from Domainex to Treat Acute Myeloid Leukemia prnasia
July 14, 2020
Invivoscribe, Inc., an industry pioneer and global leader in the field of precision diagnostics announces the launch of a fully integrated drug development engine.
On a roll with FDA approvals, Pfizer doubles down in AML with Daurismo nod fiercepharma
December 10, 2018
Make that four drug approvals for Pfizer’s oncology unit in less than two months. In a welcome streak for the pharma giant—what with Lyrica generics looming—the FDA handed out
GlycoMimetics Enrolls First Patient in Global Phase 3 Clinical Trial of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia drugs
November 29, 2018
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today dosing of the first patient in the company’s Phase 3 clinical trial of uproleselan (GMI-1271)。。。。
Tolero Pharmaceuticals Announces Clinical Research Collaboration with AbbVie for Acute Myeloid Leukemia Trial pharmafocusasia
November 27, 2018
Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for hematologic and oncologic diseases...
For first time in 40 years, cure for acute leukemia within reach worldpharmanews
August 27, 2018
Acute myeloid leukemia is one of the most aggressive cancers.
MD Anderson, Daiichi Sankyo collaborate to accelerate development of acute myeloid leukemia therapie pharmaasia
September 18, 2017
The collaboration will launch multiple phase 1 and 2 clinical trials conducted by MD Anderson with the aim of expediting delivery of new therapies.
Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemi b3cnewswire
March 20, 2017
Selvita announced that the first patient was dosed with SEL24 in a Phase I/II clinical trial, for acute myeloid leukemia (AML).